GEA 3162
Based on 1 Customer Validation
GEA 3162 is an orally active compound that acts as a NO/ONOO⁻ donor. GEA 3162 significantly inhibits the activation of human polymorphonuclear leukocytes (PMNs) through the cGMP pathway, inhibits the release of inflammatory mediators, and exerts anti-inflammatory and protective effects. GEA 3162 induces apoptosis of neutrophils and bone marrow cells by activating caspase-2/3/8/9 through the ONOO⁻ pathway. GEA 3162 has a bidirectional effect in the rat gastric ulcer model: at low doses, it significantly reduces gastric mucosal damage, while at high doses, it aggravates the ulcer area. GEA 3162 can be used for research on inflammatory conditions such as gastric ulcers.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.93%
- CAS. Nr.: 144576-10-3
- Formel: C7H4Cl2N4O
- Molecular Weight:231.04
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Pyroptosis Compound Library
HY-L059
-
Orally Active Compound Library
HY-L061
-
Cell Death Library
HY-L162
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Alle Caspase Isoform-spezifische Produkte anzeigen
MoreAlle Endogenous Metabolite Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
Caspase-2 |
Caspase-3 |
Caspase-8 |
Caspase-9 |
GEA 3162 (1-100 μM) inhibits Ca ionophore A23187-induced LTB4 and beta-glucuronidase release, chemotactic peptide FMLP-induced chemotaxis and opsonized zymosan-triggered chemiluminescence dose-dependently in human PMNs[1].
GEA 3162 (0-1 mM) inhibits LTB4 release from human PMNs dose-dependently[1].
GEA 3162 (0-1 mM) suppresses β-glucuronidase release from A23187-activated PMNs dose-dependently[1].
GEA 3162 (0-1 mM) is effective inhibitor of FMLP-induced chemotactic movement of human PMNs with IC50 value of 6 μM[1].
GEA 3162 increases the cyclic GMP levels more rapidly and at lower drug concentrations[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 144576-10-3
-
Appearance Solid
-
Molecular Weight 231.04
-
Formel C7H4Cl2N4O
-
Color Off-white to light yellow
-
SMILES
ClC1=CC=C([N+]2=NOC([NH-])=N2)C=C1Cl
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (432.83 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.82 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.82 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (274 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Moilanen E, et al. Inhibition by nitric oxide-donors of human polymorphonuclear leucocyte functions. Br J Pharmacol. 1993;109(3):852-858. [Content Brief]
[2]. Taylor EL, et al. GEA 3162 hydrochloride decomposes to co-generate nitric oxide and superoxide and induces apoptosis in human neutrophils via a peroxynitrite-dependent mechanism. Br J Pharmacol. 2004 Sep;143(1):179-85. [Content Brief]
[3]. Taylor EL, et al. GEA 3162, a peroxynitrite donor, induces Bcl-2-sensitive, p53-independent apoptosis in murine bone marrow cells. Biochem Pharmacol. 2007 Oct 1;74(7):1039-49 [Content Brief]
[4]. Asmawi MZ, Moilanen E, Annala K, Rahkonen P, Kankaanranta H. Effects of nitric oxide donors GEA 3162 and SIN-1 on ethanol-induced gastric ulceration in rats. Eur J Pharmacol. 1999 Jul 28;378(1):123-7. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.3283 mL | 21.6413 mL | 43.2825 mL | 108.2064 mL |
| 5 mM | 0.8657 mL | 4.3283 mL | 8.6565 mL | 21.6413 mL | |
| 10 mM | 0.4328 mL | 2.1641 mL | 4.3283 mL | 10.8206 mL | |
| 15 mM | 0.2886 mL | 1.4428 mL | 2.8855 mL | 7.2138 mL | |
| 20 mM | 0.2164 mL | 1.0821 mL | 2.1641 mL | 5.4103 mL | |
| 25 mM | 0.1731 mL | 0.8657 mL | 1.7313 mL | 4.3283 mL | |
| 30 mM | 0.1443 mL | 0.7214 mL | 1.4428 mL | 3.6069 mL | |
| 40 mM | 0.1082 mL | 0.5410 mL | 1.0821 mL | 2.7052 mL | |
| 50 mM | 0.0866 mL | 0.4328 mL | 0.8657 mL | 2.1641 mL | |
| 60 mM | 0.0721 mL | 0.3607 mL | 0.7214 mL | 1.8034 mL | |
| 80 mM | 0.0541 mL | 0.2705 mL | 0.5410 mL | 1.3526 mL | |
| 100 mM | 0.0433 mL | 0.2164 mL | 0.4328 mL | 1.0821 mL |
GEA 3162 Related Classifications
HY-120314 Related Classifications
Powered by Bioz